Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (301-310 of 386) with videos related to

Pageof 39
Sort By:
Molecular Cancer Therapeutics|March 19, 2008
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivoHossein Hamed, William Hawkins, Clint Mitchell, et al.
Blood|September 14, 2011
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2Xin-Yan Pei, Yun Dai, Leena E Youssefian, et al.
Cancer Biology & Therapy|January 29, 2010
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteinsHossein A Hamed, Adly Yacoub, Margaret A Park, et al.
Toxicology and Applied Pharmacology|January 9, 2007
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanomaPaul B Fisher, Devanand Sarkar, Irina V Lebedeva, et al.
Molecular Pharmacology|June 12, 2008
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutationAditi Pandya Martin, Anna Miller, Luni Emad, et al.
Molecular Cancer Research : MCR|November 16, 2021
Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma CellsLiang Zhou, Xinyan Pei, Yu Zhang, et al.
Cancer Chemotherapy and Pharmacology|March 2, 2023
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignanciesDanielle Shafer, Amanda B Kagan, Michelle A Rudek, et al.
Haematologica|October 11, 2015
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivationMohamed Rahmani, Mandy Mayo Aust, Elisa Hawkins, et al.
The Journal of Biological Chemistry|July 11, 2008
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signalingGuo Zhang, Margaret A Park, Clint Mitchell, et al.
The Journal of Biological Chemistry|September 25, 2016
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signalingGuo Zhang, Margaret A Park, Clint Mitchell, et al.
Pageof 39

Showing results (301-310 of 386) with videos related to

Sort By:
Pageof 39
Molecular Cancer Therapeutics|March 19, 2008
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivoHossein Hamed, William Hawkins, Clint Mitchell, et al.
Blood|September 14, 2011
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2Xin-Yan Pei, Yun Dai, Leena E Youssefian, et al.
Cancer Biology & Therapy|January 29, 2010
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteinsHossein A Hamed, Adly Yacoub, Margaret A Park, et al.
Toxicology and Applied Pharmacology|January 9, 2007
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanomaPaul B Fisher, Devanand Sarkar, Irina V Lebedeva, et al.
Molecular Pharmacology|June 12, 2008
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutationAditi Pandya Martin, Anna Miller, Luni Emad, et al.
Molecular Cancer Research : MCR|November 16, 2021
Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma CellsLiang Zhou, Xinyan Pei, Yu Zhang, et al.
Cancer Chemotherapy and Pharmacology|March 2, 2023
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignanciesDanielle Shafer, Amanda B Kagan, Michelle A Rudek, et al.
Haematologica|October 11, 2015
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivationMohamed Rahmani, Mandy Mayo Aust, Elisa Hawkins, et al.
The Journal of Biological Chemistry|July 11, 2008
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signalingGuo Zhang, Margaret A Park, Clint Mitchell, et al.
The Journal of Biological Chemistry|September 25, 2016
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signalingGuo Zhang, Margaret A Park, Clint Mitchell, et al.
Pageof 39